argenx SE (NASDAQ:ARGX) Shares Sold by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc cut its holdings in argenx SE (NASDAQ:ARGX) by 8.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,207 shares of the company’s stock after selling 3,702 shares during the quarter. Ensign Peak Advisors Inc owned 0.07% of argenx worth $18,151,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Blue Trust Inc. boosted its position in shares of argenx by 620.0% during the 2nd quarter. Blue Trust Inc. now owns 72 shares of the company’s stock worth $28,000 after purchasing an additional 62 shares in the last quarter. J.Safra Asset Management Corp boosted its holdings in argenx by 590.0% during the second quarter. J.Safra Asset Management Corp now owns 69 shares of the company’s stock worth $30,000 after buying an additional 59 shares in the last quarter. GAMMA Investing LLC grew its position in argenx by 420.0% during the first quarter. GAMMA Investing LLC now owns 78 shares of the company’s stock worth $31,000 after buying an additional 63 shares during the period. Mather Group LLC. purchased a new position in argenx in the first quarter valued at about $38,000. Finally, Lindbrook Capital LLC increased its holdings in argenx by 23.1% in the first quarter. Lindbrook Capital LLC now owns 197 shares of the company’s stock valued at $78,000 after buying an additional 37 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenx Trading Down 0.8 %

argenx stock opened at $528.50 on Tuesday. The stock has a fifty day moving average price of $513.92 and a 200 day moving average price of $434.04. argenx SE has a 52 week low of $327.73 and a 52 week high of $554.74. The firm has a market capitalization of $31.41 billion, a P/E ratio of -93.37 and a beta of 0.62.

argenx (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, July 25th. The company reported $0.45 EPS for the quarter, beating analysts’ consensus estimates of ($0.89) by $1.34. argenx had a negative net margin of 12.31% and a negative return on equity of 7.33%. The company had revenue of $489.43 million during the quarter, compared to the consensus estimate of $436.66 million. During the same quarter in the prior year, the company posted ($1.69) EPS. As a group, equities analysts predict that argenx SE will post -0.37 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Barclays upgraded argenx from an “equal weight” rating to an “overweight” rating in a report on Tuesday, August 6th. Robert W. Baird upped their target price on argenx from $490.00 to $515.00 and gave the company an “outperform” rating in a report on Monday, July 29th. Wedbush lifted their price target on argenx from $519.00 to $560.00 and gave the stock an “outperform” rating in a research note on Friday, July 26th. Deutsche Bank Aktiengesellschaft upgraded shares of argenx from a “hold” rating to a “buy” rating in a research report on Thursday, July 25th. Finally, Truist Financial raised their target price on shares of argenx from $480.00 to $540.00 and gave the company a “buy” rating in a report on Monday, July 22nd. Three analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, argenx currently has a consensus rating of “Moderate Buy” and an average price target of $547.74.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.